Heavy chain only antibodies to ang-2

Abstract

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.

We claim: 
     
         1 . A heavy chain only antibody (HCAb) with an antigen-binding specificity for ANG-2, wherein the HCAb comprises the amino acid sequence of SEQ ID NO:9. 
     
     
         2 . A pharmaceutical composition comprising the HCAb of  claim 1  and a pharmaceutically acceptable excipient, carrier, or diluent. 
     
     
         3 . The HCAb of  claim 1 , wherein the HCAb VH region comprises the amino acid sequence of SEQ ID NO: 25. 
     
     
         4 . The HCAb of  claim 3 , wherein the HCAb is human or humanized. 
     
     
         5 . A pharmaceutical composition comprising the HCAb of  claim 4  and a pharmaceutically acceptable excipient, carrier, or diluent. 
     
     
         6 . A method of treating an ophthalmologic disorder comprising administering to a subject in need thereof a HCAb having a VH region comprising the amino acid sequence of SEQ ID NO: 25. 
     
     
         7 . The method of  claim 6 , wherein the HCAb comprises the amino acid sequence of SEQ ID NO:9. 
     
     
         8 . The method of  claim 7 , wherein the ophthalmologic disorder comprises age-related macular degeneration (AMD), choroidal neovascularization (CNV), cystoid macula edema (CME), myopia-associated choroidal neovascularization, vascular streaks, proliferative diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR), diabetic macular edema (DME), macular edema, retinal vein occlusion, abnormal corneal angiogenesis, pterygium conjunctivae, subretinal edema, or intraretinal edema. 
     
     
         9 . The method of  claim 8 , wherein the abnormal corneal angiogenesis is as a result of keratitis, corneal transplantation, keroplasty, or hypoxia. 
     
     
         10 . The method of  claim 6 , wherein the ophthalmologic disorder is AMD, and wherein the HCAb VH region comprises SEQ ID NO: 25. 
     
     
         11 . The method of  claim 10 , wherein the ophthalmologic disorder is AMD, and wherein the HCAb comprises SEQ ID NO: 9. 
     
     
         12 . The method of  claim 6 , wherein the ophthalmologic disorder is abnormal corneal angiogenesis, and wherein the HCAb VH region comprises SEQ ID NO: 25. 
     
     
         13 . A method of treating AMD comprising administering to a subject in need thereof a HCAb comprising SEQ ID NO: 9.